Copyright: ©Author(s) 2026.
World J Gastroenterol. Aug 7, 2026; 32(29): 119809
Published online Aug 7, 2026. doi: 10.3748/wjg.119809
Published online Aug 7, 2026. doi: 10.3748/wjg.119809
Figure 1 Comparison of progression-free survival and overall survival among the three groups.
A: Progression-free survival; B: Overall survival. PSOX: Nab-paclitaxel plus oxaliplatin and S-1; SOX + XDL: Oxaliplatin plus S-1 combined with sintilimab; CAPOX: Capecitabine plus oxaliplatin.
Figure 2 Progression-free survival nomogram.
RECIST: Response Evaluation Criteria in Solid Tumors; TRG: Tumor regression grade; PFS: Progression-free survival; cTNM: Clinical tumor-node-metastasis.
Figure 3 Progression-free survival receiver operating characteristic curve.
A: 18-month training and validation set; B: 24-month training and validation set; C: 36-month training and validation set; D: Concordance index over time.
Figure 4 Calibration curve for progression-free survival.
A-C: Training set (18 months, 24 months, 36 months); D-F: Validation set (18 months, 24 months, 36 months).
Figure 5 Decision curve analysis curves of progression-free survival.
A-C: Training set (18 months, 24 months, 36 months); D-F: Validation set (18 months, 24 months, 36 months).
- Citation: Zhou DX, Jiang SW, Zhang CG, Cai BJ, Lv HD. Perioperative SOX plus sintilimab vs P-SOX and CAPOX in advanced gastric cancer: A real-world comparison. World J Gastroenterol 2026; 32(29): 119809
- URL: https://www.wjgnet.com/1007-9327/full/v32/i29/119809.htm
- DOI: https://dx.doi.org/10.3748/wjg.119809